Advanced liver cancer: Biologic combo ‘yields longest survival yet’
The median duration of response of one year is 'remarkable for liver cancer', a leading specialist says
The combination of atezolizumab and bevacizumab has yielded the longest overall survival ever seen in a phase 3 study of patients with advanced hepatocellular carcinoma (HCC), researchers say.
The IMbrave150 trial enrolled 501 patients with nonresectable, treatment-naive HCC.
Patients were randomly allocated in a 2:1 ratio to three-weekly atezolizumab (1200mg IV) plus bevacizumab (15mg/kg IV) or an existing first-line treatment, sorafenib (400 mg twice daily).
Results of the primary analysis, favouring the combination therapy, were published in the New England Journal of Medicine in May 2020.
